# Effect of Oral Propranolol on mRNA Expresssion in Symptomatic Cavernous Malformation

> **NCT03474614** · PHASE2 · TERMINATED · sponsor: **St. Joseph's Hospital and Medical Center, Phoenix** · enrollment: 4 (actual)

## Conditions studied

- Cerebral Cavernous Malformations

## Interventions

- **DRUG:** Propranolol
- **GENETIC:** DNA and RNA Analysis

## Key facts

- **NCT ID:** NCT03474614
- **Lead sponsor:** St. Joseph's Hospital and Medical Center, Phoenix
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-01-24
- **Primary completion:** 2021-02-11
- **Final completion:** 2021-02-11
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** lack of accrual
- **Last updated:** 2024-04-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03474614

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03474614, "Effect of Oral Propranolol on mRNA Expresssion in Symptomatic Cavernous Malformation". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03474614. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*